Health Trials

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

ConditionRhabdomyosarcoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity of Birmingham

About this trial

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Eligibility criteria

Qualifiers

Histologically confirmed diagnosis of RMS (except pleomorphic RMS)

Written informed consent from the patient and/or the parent/legal guardian

Entered in to the FaR-RMS study at diagnosis

Very High Risk disease

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Irinotecan
  • Actinomycin D
  • Doxorubicin
  • Ifosfamide
  • Vincristine
  • Vinorelbine
  • Cyclophosphamide
  • Temozolomide
  • radiotherapy
  • Regorafenib

Treatment groups

1,672 Participants
are divided into 19 treatment groups

19

Treatment groups

See each treatment group below.

Sponsors and collaborators

University of Birmingham

Lead sponsor

Source ClinicalTrials.gov